July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Intravitreal aflibercept treatment in a population of different subtypes of exsudative maculopathy
Author Affiliations & Notes
  • Guenther Weigert
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Sandra Rezar
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Katharina Eibenberger
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Wolf Buehl
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Ursula Schmidt-Erfurth
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Stefan Sacu
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships   Guenther Weigert, Bayer (F); Sandra Rezar, None; Katharina Eibenberger, None; Wolf Buehl, Bayer (F); Ursula Schmidt-Erfurth, Bayer (C), Genentech (C), Novartis (C), Roche (C); Stefan Sacu, Allergan (F), Bayer (F), pharmaselect (F)
  • Footnotes
    Support  Research grant from Bayer
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 818. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Guenther Weigert, Sandra Rezar, Katharina Eibenberger, Wolf Buehl, Ursula Schmidt-Erfurth, Stefan Sacu; Intravitreal aflibercept treatment in a population of different subtypes of exsudative maculopathy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):818.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To prospectively evaluate the morphological and functional outcome of intravitreal aflibercept monotherapy in patients with different subtypes of exsudative maculopathy.

Methods : 44 eyes of consecutive treatment-naïve patients with polypoidal choroidal vasculopathy (PCV, n=12), hemorrhagic choroidal neovascularization (hCNV, n=12), pigment epithelium detachment (PED, n=11) and retinal angiomatous proliferation (RAP, n=9) were included in this prospective analysis. All patients received three initial aflibercept 2mg/0.05ml injections (Eylea®) in monthly intervals (loading phase) and were subsequently treated until month 12. Monthly follow up visits were scheduled to evaluate best corrected visual acuity and central retinal thickness changes using OCT.

Results : Mean baseline VA was 65±16 letters (67±16 PCV; 55±21 hCNV; 74±7 PED and 64±11 RAP). After 6 months VA was 70±14 (p>0.05) and after 12 months 68±17 letters (p=0.3) (66±17 PCV; 69±18 hCNV; 69±19 PED and 68±13 RAP at month 12). Mean central retinal thickness (CRT) was 531±181 µm at baseline (523±251µm PCV; 497±171µm hCNV; 541±158 PED and 573±132µm RAP). CRT decreased to 365±112µm after 6 months (p<0.001) and to 354±136µm after 12 months (p<0.001; 310±97µm PCV; 323±79µm hCNV; 422±158µm PED and 357±185µm RAP at month 12). During the study period, the patients received a mean of 6±2 intravitreal aflibercept injections.

Conclusions : Aflibercept monotherapy was effective regarding anatomical improvement and stabilization of visual function in patients with subtypes of exsudative maculopathy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×